Brieven van een gemobiliseerde 1939-1940 : de mobilisatie van 1939-1940 op Fort bij Rhijnauwen en Fort bij Vleuten

Via bewaard gebleven brieven van kapitein Klaas Brouwer, destijds commandant van het 2e bataljon van het 25e Regiment Infanterie, komen vrijwel onbekende gebeurtenissen op de Houtensche Vlakte tijdens de mobilisatie 1939-1940 tot leven en krijgen nieuwe inhoud

Urine profile analysis by field desorption mass spectrometry, a technique for detecting metabolites of xenobiotics. Application to 3,5-dinitro-2-hydroxytoluene

A technique for the detection of biotransformation products of xenobiotics in crude urine extracts by field desorption mass spectrometric profile analysis is described. The method comprises determination of peak profiles of a series of blank and test samples using low resolution field desorption mass spectrometry, comparison of averaged peak profiles and noise reduction by means of Fisher and ratio weighting of peak intensities. Application of the technique to 3,5-dinitro-2-hydroxytoluene has resulted in the detection of two hitherto unknown metabolites in rat urine. By thin-layer co-chromatography, high resolution electron impact mass spectrometry and thin-layer chromatographic-field desorption mass spectrometric analysis they could be identified as 3,5-dinitro-2-hydroxybenzenemethanol and 3,5-diacetamido-2-hydroxytoluene. Chemicals/CAS: dinitro ortho cresol, 534-52-1; Cresols; Dinitrocresols; hedolit, 534-52-

Isolation and identification of an O-(2-hydroxypropyl)-maltose from the faeces of rats fed with O-(hydroxypropyl)starch

When rats were fed with diets containing hydroxypropylated potato-starches with a degree of substitution up to 0.11, the major metabolite, isolated from the faeces, was shown by mass spectrometry and p.m.r. spectrometry of its peracetate to be 4-O-{2-O-[(RS)-2-hydroxypropyl]-α-D-glucopyranosyl}-D-glucopyranose

COLQ variant associated with Devon rex and Sphynx feline hereditary myopathy

Some Devon Rex and Sphynx cats have a variably progressive myopathy characterized by appendicular and axial muscle weakness, megaesophagus, pharyngeal weakness and fatigability with exercise. Muscle biopsies from affected cats demonstrated variable pathological changes ranging from dystrophic features to minimal abnormalities. Affected cats have exacerbation of weakness following anticholinesterase dosing, a clue that there is an underlying congenital myasthenic syndrome (CMS). A genome-wide association study and whole-genome sequencing suggested a causal variant for this entity was a c.1190G>A variant causing a cysteine to tyrosine substitution (p.Cys397Tyr) within the C-terminal domain of collagen-like tail subunit (single strand of homotrimer) of asymmetric acetylcholinesterase (COLQ). Alpha-dystroglycan expression, which is associated with COLQ anchorage at the motor end-plate, has been shown to be deficient in affected cats. Eighteen affected cats were identified by genotyping, including cats from the original clinical descriptions in 1993 and subsequent publications. Eight Devon Rex and one Sphynx not associated with the study were identified as carriers, suggesting an allele frequency of ~2.0% in Devon Rex. Over 350 tested cats from other breeds did not have the variant. Characteristic clinical features and variant presence in all affected cats suggest a model for COLQ CMS. The association between the COLQ variant and this CMS affords clinicians the opportunity to confirm diagnosis via genetic testing and permits owners and breeders to identify carriers in the population. Moreover, accurate diagnosis increases available therapeutic options for affected cats based on an understanding of the pathophysiology and experience from human CMS associated with COLQ variants